Print this page
-
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2
Expression
Protocol: 072305Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Pancreas -
Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial.
Protocol: 072306Principal Investigator:
-
Brett Ecker
Applicable Disease Sites: Other Digestive Organ -
A Phase II, open-label, multi-cohort, multicenter study in patients with unresectable HEPATOCELLULAR CARCINOMA and CHILDPUGH B7 and B8 Cirrhosis
Protocol: 072309Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Liver -
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors.
Protocol: 072310Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Prostate
Rectum
Small Intestine -
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Protocol: 072311Principal Investigator:
-
Sharon Li
Applicable Disease Sites: Liver -
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers Big Ten Cancer Research Consortium BTCRC-GI22-564
Protocol: 072401Principal Investigator:
-
Howard Hochster
Applicable Disease Sites: Small Intestine -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Protocol: 072403Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Pancreas -
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy.
Protocol: 081602Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined with Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men with Newly Diagnosed Metastatic Prostate Cancer. (Multi-center)
Protocol: 081707Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Prostate -
A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer.
Protocol: 081805Principal Investigator:
-
Lara Hathout
Applicable Disease Sites: Prostate -
Endogenous Retrovirus Expression, Chromatin Abnormalities and Response to Immune Checkpoint Blockade in Clear Cell Renal Cell Cancer.
Protocol: 081909Principal Investigator:
-
Shridar Ganesan
Applicable Disease Sites: Other Urinary -
Cyto-KIK TRIAL: (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).
Protocol: 082002Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Kidney -
Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy.
Protocol: 082003Principal Investigator:
-
Lara Hathout
Applicable Disease Sites: Prostate -
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*).
Protocol: 082101Applicable Disease Sites: Prostate
-
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE).
Protocol: 082104Principal Investigator:
-
Tina Mayer
Applicable Disease Sites: Prostate -
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Protocol: 082105Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Prostate